TREATMENT
Metronomic chemotherapy plus regorafenib tested in treatment-resistant metastatic colorectal cancer — ESMO Gastrointestinal Oncology
The REPROGRAM-01 single-arm phase II trial tested regorafenib combined with metronomic capecitabine, cyclophosphamide, and aspirin in refractory metastatic colorectal cancer. This approach aims to improve outcomes in heavily pre-treated patients by combining different mechanisms of action.
For patients whose cancer has progressed through multiple lines of treatment, this combination approach may offer a new option. The gradual dose escalation strategy for regorafenib may also help manage side effects better than standard dosing.